ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO635

Sparsentan Pharmacokinetics and Pharmacodynamics as the Basis of Dose Selection for Primary Focal Segmental Glomerular Sclerosis (FSGS)

Session Information

Category: Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics

  • 1601 Pharmacokinetics, Pharmacodynamics, Pharmacogenomics

Authors

  • Karol, Michael, Retrophin, Inc., Cambridge, Massachusetts, United States
  • Pan-Zhou, Xin-Ru, Retrophin, Inc., Cambridge, Massachusetts, United States
  • Tuller, Sarah E., Retrophin, Inc., Cambridge, Massachusetts, United States
  • Komers, Radko, Retrophin, Inc., Cambridge, Massachusetts, United States
Background

Sparsentan’s dual action is being studied for potential use in the treatment of primary FSGS. This analysis was performed to assess the dose/pharmacokinetic (PK)/pharmacodynamic (PD) relationship of sparsentan in FSGS patients enrolled in the DUET trial, to guide future dose selection.

Methods

The DUET trial determined the sparsentan-induced changes in urine protein/creatinine ratio (Up/C), (baseline to Week 8) in patients assigned to 200 (n=13), 400 (n=21), or 800 (n=30) mg/day. The relationship between sparsentan dose or area under the curve (AUC), and change in Up/C was assessed. PK/PD analyses were based on actual doses received, accounting for dose reductions resulting in PK/PD sample sizes of 17, 23, and 22 for 200, 400, and 800 mg/day, respectively.

Results

Due to small sample sizes, antiproteinuric effects across sparsentan doses were not statistically distinguishable; however, likelihood of a patient having drug exposures resulting in a decrease in Up/C was greater for the 800 mg dose. For the three dose groups, the percentages of patients with a decrease in Up/C were 76%, 74%, and 91%, respectively, as shown in the Figure. Of the 30 patients assigned to the 800 mg dose, 18% experienced hypotension. In general, sparsentan was safe and well tolerated with no clinically significant changes in vital signs or major clinically significant abnormalities in laboratory tests.

Conclusion

Initial daily dosing at 400 mg, followed by escalation to 800 mg for those that tolerate 400 mg, increases the likelihood of antiproteinuric effect while maximizing safety. Both the therapeutic effect vs dose or AUC and AUC distribution analyses each led to the same conclusion.

Funding

  • Commercial Support